Spectral Medical Inc. (TSX: EDT), a late-stage theranostic company focused on sepsis and septic shock treatment, has provided an update following its in-person 100-Day Meeting with the U.S. Food and Drug Administration regarding its Premarket Approval application for Toraymyxin™. The FDA did not request an additional clinical trial following its 100-day review, a development investors may view as a meaningful positive signal. The company stated it does not currently expect the additional regulatory activities to result in a material change to its overall regulatory timeline.

Key Points

  • Spectral Medical Inc. (TSX: EDT) is a Toronto-based late-stage theranostic company advancing Toraymyxin™ for U.S. FDA approval
  • The FDA issued a deficiency letter ahead of the 100-Day Meeting, identifying items requiring additional information, analyses, testing, and clarification
  • The FDA did not request an additional clinical trial as part of the company's required response
  • Investors will be watching for FDA's official meeting minutes and Spectral's finalised work plan and timing updates

FDA Deficiency Letter Sets Scope for PMX PMA Response

Prior to the in-person 100-Day Meeting, the FDA issued Spectral Medical a deficiency letter identifying items requiring additional information, analyses, testing, and clarification. The company notes that deficiency letters are commonly issued as part of the standard 100-day PMA review process and serve to focus discussions on outstanding items. Spectral described the meeting as constructive and stated it now has further clarity on the analyses and activities required to advance the PMA review. The FDA's official minutes of the meeting, which represent the definitive record of the discussion, had not yet been issued as of the announcement date.

No Additional Clinical Trial Required, Regulatory Timeline Intact

A key outcome disclosed in the release is that the FDA did not request an additional clinical trial as part of Spectral's response to the deficiency letter. The company also stated that, based on its current assessment, it does not currently expect the additional required activities to result in a material change to its overall regulatory timeline. Spectral indicated it is actively progressing the additional analyses, testing, and other activities discussed with the FDA and is finalising the associated work plan and timing. The company stated it will provide further updates as appropriate.

Toraymyxin™ Product Background and Global Commercial Footprint

Toraymyxin™ is a therapeutic hemoperfusion device designed to remove endotoxin from the bloodstream in patients with septic shock. The product is approved for therapeutic use in Japan and Europe and is licensed by Health Canada. According to the release, more than 360,000 units have been sold worldwide to date. The FDA granted Breakthrough Device Designation for the product in July 2022 for the treatment of endotoxic septic shock. Spectral's complementary FDA-cleared Endotoxin Activity Assay (EAA™) is described as the only FDA-cleared blood endotoxin test.